Novo Nordisk Q1 May 6 Detail: Wegovy at 65% of US New GLP-1 Prescriptions — CEO Calls It 'Turnaround Situation'; Single-Chamber CagriSema Co-Formulation Discontinued
Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.